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Chondrosarcoma of the head and neck region is a rare
disease, representing approximately 0.1% of all head and neck
neoplasms. The 5-year survival rate of chondrosarcoma is 70-
80%, showing relatively good prognosis; however, it is known
to progress slowly and eventually cause multiple metastases.
In this study, we reviewed chondrosarcoma cases experienced
at Yonsei University Medical College during the last 15 years
to investigate its clinical characteristics and treatment outcome.
The medical records of 8 patients who were diagnosed with
chondrosarcoma of the head and neck region and underwent
surgical treatment between December 1990 and December
2002 were retrospectively reviewed. The primary sites were
sinus, mastoid, jugular foramen and thyroid cartilage. In all
patients, the initial treatment modality was surgery, and
postoperative radiation therapy was performed in 4 cases. The
pathological findings showed chondrosarcoma in 7 cases and
mesenchymal chondrosarcoma in 1 case. The treatment out-
come resulted in 3 cases of recurrence, of which 2 cases were
treated successfully and the other case expired of disease,
indicating a survival rate of 87.5%. In the case that resulted
in death, complete excision could not be achieved. Therefore,
we concluded that wide excision is a beneficial initial
treatment of this rare disease.
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INTRODUCTION
Chondrosarcoma of the head and neck region is
a rare disease, representing approximately 0.1% of
all head and neck neoplasms.1 This malignant
tumor, in which the tumor cells form chondroid
matrix, represents 10-20% of primary bone tu-
mors and is the second most common sarcoma of
bone origin.2,3 Due to the low incidence of this
disease, there have been few studies with large
numbers of subjects, and therefore, various results
have been reported.4-6 In this study, we reviewed
cases of chondrosarcoma experienced at Yonsei
University Medical College during the last 15
years to determine the clinical manifestations,
treatment methods and treatment results of this
uncommon disease.
MATERIALS AND METHODS
Using the cancer registration for reference,
patients who were admitted to our institute
between 1990 and 2003, and whose final diagnosis
at discharge was chondrosarcoma, were reviewed.
There were 100 cases of chondrosarcoma and of
those, the head and neck region was the primary
site in only 8 cases. The charts were reviewed
retrospectively in terms of chief complaint, pri-
mary site, treatment modality, pathology finding,
recurrence, follow-up and treatment results.
RESULTS
2010 patients were diagnosed with head and
neck neoplasms at our institute from 1990 to 2003
and of these, there were only 8 cases of chon-
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Table 2. Chondrosarcoma of the Head and Neck by
Site
Site Number
Paranasal sinuses 4
Temporal bone 3
Larynx 1
Total 8
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drosarcoma, which represents 0.4% of all head
and neck cancers. Of the 8 cases, 4 were male and
4 were female, with a mean age of 40 years
ranging from 24 to 60. The follow-up period
ranged from 25 months to 171 months with a
mean of 76.5 months (Table 1). The primary sites
were paranasal sinuses, temporal bone and larynx
(Table 2). The chief complaints at the time of first
visit were related to the primary sites, such that
an ethmoid sinus origin tumor presented with
ocular symptoms, maxillary and jugular foramen
origin tumors with facial swelling, a mastoid
origin tumor with facial paralysis, and a thyroid
cartilage origin tumor with neck mass. Patholo-
gically, of the 8 cases of head and neck chondro-
sarcoma, 7 were conventional chondrosarcoma
and 1 was mesenchymal chondrosarcoma. Of the
7 cases of conventional chondrosarcoma, 2 were
grade I, 4 were grade II and 1 was grade III (Fig.
1 and 2). Surgery was performed as the initial
treatment modality in all cases. Radiotherapy was
applied in 4 cases, which included 2 cases of
recurrence and 2 cases with positive resection
margin. The 2 cases with positive resection mar-
gin were successfully treated after radiotherapy.
Recurrence occurred in 3 cases. The pathological
grade of all 3 cases was grade II and salvage
treatment was performed in every case. Of the
recurred cases, the case of mastoid origin tumor
was successfully treated surgically with a
transmastoid approach, whereas in the case of
maxillary sinus origin, successful salvage was
achieved 7 years from the point of diagnosis after
receiving chemoradiation therapy and bilateral
maxillectomy. However, the case of thyroid
cartilage origin recurred in the tonsil 13 months
Table 1. Clinical Characteristics of Head and Neck Chondrosarcoma
Case Age Sex CC Site Treatment Pathology Grade Margin Recur
F/U
(month)
Outcome
1 34 M Epiphora Ethmoid
sinus
Craniofacial resection
& postop. RTx
Chondrosarcoma II + No 111 NED
2 56 F Visual
loss
Ethmoid
sinus
Medial maxillectomy
& ethmoidectomy &
postop. RTx
Chondrosarcoma III + No 30 NED
3 29 F Facial
swelling
Maxillar
y sinus
Subtotal
maxillectomy
Mesenchymal
chondrosarcoma
- No 25 NED
4 26 M Facial
swelling
Maxillar
y sinus
Partial maxillectomy Chondrosarcoma II - Yes 171 NED
5 24 F Facial
palsy
Mastoid
bone
Mass excision via
transmastoid
approach
Chondrosarcoma II - Yes 40 NED
6 49 F Facial
palsy
Mastoid
bone
ITFA type C Chondrosarcoma I - No 51 NED
7 42 M Facial
swelling
Jugular
foramen
ITFA type A Chondrosarcoma I - No 130 NED
8 60 M Neck
mass
Thyroid
cartilage
Mass excision Chondrosarcoma II - Yes 54 DOD
CC, chief complaint; F/U, follow-up; NED, no evidence of disease; DOD, died of disease; ITFA, infratemporal fossa approach.
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after the initial treatment. Despite treatment with
radiotherapy and two salvage operations, death
occurred 54 months after diagnosis because of
failure to completely excise the tumor at the last
operation due to anatomical reasons. Seven of
eight cases have no current evidence of disease,
and the survival rate is 87.5% (Table 1).
DISCUSSION
Chondrosarcoma is a slow growing but malig-
nant tumor with a relatively high local recurrence
rate. Chondrosarcoma represents 10 to 20% of all
malignant bone tumors and of these, 1 to 12%
originate in the head and neck region.6,7 This
tumor can originate from cartilage and soft tissue
as well as bone with common primary sites being
the pelvic bone and long bones, such as the
femur.8 The common primary sites in the head
and neck region include the mandible, nasal
cavity, sinus, and maxilla; however, it is generally
accepted that the tumor mostly arises from bony
tissue of the head and neck.1,5,6,9 In this study, the
8 cases were all of bone origin except for one case
that originated from thyroid cartilage. The
precipitating factors of this tumor are multiple
hereditary exostosis, Ollier's disease, Maffucci's
syndrome, previous intravenous thoratrast con-
trast use, Paget's disease of bone, chondromyxoid
fibroma, and previous irradiation, but none of
these factors were found in this study.5 Chon-
drosarcoma has a slight male predilection10 and
occurs most commonly between the 4th and 7th
decades.11 Chondrosarcomas of cartilaginous or
soft tissue origin are more common in males and
in patients over 50 years of age, whereas those of
bone origin have higher incidence in females and
in patients less than 50 years of age.1 According
to one report, the rates of lymph node and distant
metastasis were relatively low: 5.6% and 6.7%,
respectively. In addition, metastasis was usually
observed in patients who had undergone multiple
operations over a long period of time.1 In this
study, no case of metastasis was seen among the
8 cases, including the 3 patients who received
multiple salvage operations.
Chondrosarcomas show various histological
patterns ranging from benign chondroid tumor to
undifferentiated neoplasm, which make them
difficult to diagnose pathologically.
10
Evans et al.
classified chondrosarcomas into 3 grades, from
grade I to grade III, according to cellular density,
nuclear differentiation, and the size of nucleus.
This classification is still currently used.12 Never-
theless, there have been efforts to classify chon-
drosarcomas simply into high grade and low
grade for better correlation with prognosis.1 In
this study, no recurrence occurred in grade I
tumors, showing a relatively good correlation
between tumor grade and prognosis. Chondrosar-
coma has several histological types, of which the
conventional type is the most common. Other
types include clear cell, myxoid, mesenchymal
and dedifferentiated variants.
13
The clear cell
variant is otherwise called malignant chondro-
Fig. 1. Chondrosarcoma infiltrating the marrow space and
surrounding preexisting bony trabeculae. Hematoxylin &
Eosin, ×14.
Fig. 2. Conventional chondrosarcoma grade II. Hema-
toxylin & Eosin, ×100.
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blastoma, but there has been controversy over
whether to classify it as a variant of chondro-
sarcoma or to separately categorize it as malignant
chondroblastoma.14 Although there differences
exist among reports, the myxoid variant is known
to originate from soft tissues rather than bone
tissues.15 The mesenchymal variant is also called
the aggressive variant, since 2/3 of cases present
before the age of 30, and in advanced stages and
grades.16 The only patient with mesenchymal
chondrosarcoma in this study was a young female
aged in the 3rd decade. Dedifferentiated chondro-
sarcoma characteristically contains an anaplastic
component histologically. In addition, chondro-
sarcomas of the larynx have several characteristics
that distinguish them from those of different
origin: they are low grade tumors, presentation
occurs after 50 years of age, and they have a better
prognosis compared to bone origin chondro-
sarcomas of the head and neck region.17
Surgical treatment is known as the most
effective treatment modality for chondrosarcoma.
The most important point in performing surgery
is to ensure an adequate safety margin histolo-
gically since residual disease is known to be an
important cause of recurrence. In general, the
principle technique for extralaryngeal chondro-
sarcoma is a wide bloc resection, whereas that for
laryngeal chondrosarcoma is conservative resec-
tion. The reason for this is that laryngeal chon-
drosarcoma is usually of low grade, showing a
relatively favorable prognosis so that mass
excision without total laryngectomy is sufficient to
achieve an acceptable survival through salvage
surgery.1,18 Neck dissection is not routinely per-
formed because of a low incidence of lymph node
metastasis. Concerning the radiosensitivity of
chondrosarcoma, diverse opinions have been re-
ported, ranging from radioresistant to radiosen-
sitive and even curative.
19
However, it is generally
accepted that radiotherapy should be used for
palliative purpose in unresectable cases, or as an
adjuvant therapy in cases of residual disease
rather than as an initial treatment.20,21 Chemo-
therapy has a limited role in chondrosarcoma, but
can be applied as an adjuvant therapy in high
grade mesenchymal chondrosarcomas, in cases of
rapid local recurrence with aggressive behavior,
or in cases with potential for metastasis.6 In this
study, all 8 cases were initially treated with
surgery and of these, 4 cases were treated suc-
cessfully with surgery alone. The 2 patients who
had residual disease after initial treatment re-
ceived radiotherapy and are disease free at the
present day, suggesting that radiotherapy does
have some role in controlling the disease.
The survival rate of chondrosarcoma is reported
as 44-87%,4,11,22 and there are two possible expla-
nations for this wide range. One is that it is hard
to perform large-scale studies due to the rarity of
this disease. The other is that the survival rate has
improved a great deal recently thanks to the
advancement in radiographic imaging and sur-
gical technique. The survival rate in this study
was 87.5%, which is relatively high compared
with other reports. The prognostic factors of
chondrosarcoma are resectability, stage, grade and
primary site, while myxoid and mesenchymal
variants are known for their poor prognosis.1,5 The
most important prognostic factor is resectability,
which makes complete excision of the tumor the
single most significant factor in determining the
prognosis. This is also supported by the fact that
the most common cause of death in chondrosar-
coma is local recurrence, not metastasis. The cause
of death of the case in this study was residual
disease that remained because of an inability to
ensure an adequate safety margin at the last
operation, despite multiple previous operations.
In cases of recurrence, chondrosarcoma grows
progressively for more than 2 years from recur-
rence to death. Aggressive surgical treatment
should be considered, even for recurrent tumors,
since the usual pattern of recurrence is local
failure and not metastasis. In this study, all 3
cases of recurrence received aggressive treatment
including surgery, and 2 of the 3 cases were suc-
cessfully salvaged. One of the recurred cases was
salvaged 7 years after receiving multiple treat-
ments due to multiple recurrences. There was no
evidence of metastasis during the 7 years, proved
the slow-growing nature of the disease with low
incidence of metastasis. Moreover, this example
demonstrates the importance of local control
during treatment.
Chondrosarcoma of the head and neck region is
such an uncommon disease that we only experi-
enced 8 cases during a 15-year period. This dis-
Sei Young Lee, et al.
Yonsei Med J Vol. 46, No. 2, 2005
ease has a slow-growing nature with low in-
cidence of metastasis. Therefore, we conclude that
complete excision of the primary site is of utmost
importance for successful treatment. Although the
number of cases was small, and despite consider-
able controversy, we speculate that postoperative
radiotherapy may have some role in the treatment
of chondrosarcoma, considering the 2 cases re-
ported here with positive margin that were suc-
cessfully treated with postoperative radiotherapy.
REFERENCES
1. Koch BB, Karnell LH, Hoffman HT, Apostolaskis LW,
Robinson RA, Zhen W, et al. National cancer database
report on chondrosarcoma of the head and neck. Head
Neck 2000;22:408-25.
2. Fechner RE, Mills SE. Atlas of tumor pathology. 3rd
series. Fascicle 8: Armed Forces Institute of Pathology;
1993.
3. Barnes R, Catto M. Chondrosarcoma of bone. J Bone
Joint Surg 1966;48:729-64.
4. Finn DG, Goepfert H, Batsakis JG. Chondrosarcoma of
the head and neck. Laryngoscope 1984;94:1539-44.
5. Burkey BB, Hoffman HT, Baker SR, Thornton AF,
McClatchey KD. Chondrosarcoma of the head and
neck. Laryngoscope 1990;100:1301-5.
6. Ruark DS, Schlehaider UK, Shah JP. Chondrosarcomas
of the head and neck. World J Surg 1992;16:1010-6.
7. Garrington GE, Collett WK. Chondrosarcoma I. litera-
ture review. J Oral Pathol 1988;17:1-11.
8. McCoy JM, McConnel F. Chondrosarcoma of the nasal
septum. Arch Otolaryngol 1981;107:125-7.
9. Weiss WW, Bennett JA. Chondrosarcoma: a rare tumor
of the jaws. J Oral Maxilllofac Surg 1986;44:73-9.
10. Batsakis JG, Solomon AR, Rice DH. The pathology of
head and neck tumors: neoplasm of cartilage, bone, and
the notochord, part 7. Head Neck Surg 1980;3:43-57.
11. Arlen M, Toleefsen HF, Huvos AG, Marcove RC.
Chondrosarcoma of head and neck. Am J Surg 1970;
120:456-60.
12. Evans HL, Ayala AG, Romsdahl MM. Prognostic
factors in chondrosarcoma of bone. Cancer 1977;40:818-
31.
13. Huvos AG, Marcove RC. Chondrosarcoma in the
young: A clinicopathologic analysis of 79 patients
younger than 21 years of age. Am J Surg Pathol 1987;
11:930-42.
14. Bjornsson J, Unni KK, Dahlin DC, Beabout JW, Sim FH.
Clear cell chondrosarcoma of bone. Observation in 47
cases. Am J Surg Pathol 1984;8:223-30.
15. Abramavoci LC, Steiner GC, Bonar F. Myxoid chon-
drosarcoma of soft tissue and bone: A retrospective
study of 11 cases. Hum Pathol 1995;26:1215-20.
16. Lichtenstein L, Bernstein D. Unusual benign and
malignant chondroid tumors of bone: A survey of some
mesenchymal cartilage tumors and malignant chon-
droblastic tumors, including a few multicentric ones as
well as many atypical benign chondroblastomas and
chondromyxoid fibromas. Cancer 1983;52:533-41.
17. Kozelsky TF, Bonner JA, Foote RL, Olsen KD,
Kasperbauer JL, Mc Caffrey TV, et al. Laryngeal chon-
drosarcomas: the Mayo clinic experience. J Surg Oncol
1997;65:269-73.
18. Lewis JE, Olsen KD, Inwards CY. Cartilaginous tumors
of the larynx: clinicopathologic review of 47 cases. Ann
Otol Rhinol Laryngol 1997;106:94-100.
19. Harwood AR, Cummings BJ, Fitzpatrick PJ. Radio-
therapy for unusual tumors of the head and neck. J
Otolaryngol 1984;13:391-4.
20. Harwood AR, Krajbich JI, Fornasier VL. Radiotherapy
of chondrosarcoma of bone. Cancer 1980;45:2769-77.
21. McNaney D, Lindberg RD, Ayala AG, Barkley HT Jr,
Hussey DH. Fifteen year radiotherapy experience with
chondrosarcoma of bone. Int J Radiat Oncol Biol
Physiol 1982;8:187-90.
22. Fu YS, Perzin KH. Non-epithelial tumors of the nasal
cavity, paranasal sinuses, and nasopharynx: A clinico-
pathologic study. III. Cartilaginous tumors. Cancer
1974;34:453-63.
